CAPRO™ Platform
Patented polymer excipient · Release by design
MORE™ Platform
Patent-pending oral wafer · OTC + Rx
Long-Acting Injectables
SubQ · IM · IA · Biodegradable implant

Transforming how
therapeutics are delivered.

Trekka partners with pharma and consumer health companies to solve their hardest formulation challenges — solubility, stability, loading, bioavailability, and controlled release — across small molecule drugs, biologics and drug combinations, using two proprietary biomaterial platforms that go where no legacy excipient can go.

CAPRO™ — patent granted MORE™ Patent pending GMP-compatible processes 505(b)(2) regulatory strategy
BROAD Applications TREKKA PLATFORMS CAPRO™ Excipient Platform MORE™ Oral Wafer Platform
We solve
Poor solubility
BCS II & IV molecules
Biologic instability
Peptides, proteins, vaccines
Short half-life
Frequent dosing, poor adherence
Burst release
Toxic peaks, rapid depletion
Wrong format
Pills, tablets, cold-chain vaccines
See how we solve them
The formulation problem

The majority of drugs are limited
by delivery — not by their pharmacology.

Poor solubility, biologic instability, uncontrolled release, and format limitations keep promising molecules from reaching their potential. That is the market CAPRO™ and MORE™ were built to address.

40%
of marketed drugs
Have poor water solubility — directly limiting bioavailability, in vivo efficacy, and safety for hundreds of millions of patients.
90%
of pipeline drugs
Face BCS Class II or IV solubility challenges — the single most common reason molecules fail before they reach patients.
>$145B
BCS IV small molecule market
Stranded value in molecules with confirmed pharmacology that existing excipient technology cannot adequately formulate.
$200B
Biologics market
Peptides, proteins, vaccines, and nucleic acids — all susceptible to the instability, cold chain, and delivery limitations CAPRO™ eliminates.
CAPRO™ and MORE™ were designed from the ground up to address this — not as incremental improvements to legacy platforms, but as fundamentally different polymer architectures.
CAPRO™ is a new excipient class — patented biodegradable polymers with functional blocks and cleavable linkers that pre-program release kinetics without harmful solvents, acidic byproducts, or API modification. MORE™ is a patent-pending multi-layer oral wafer enabling transmucosal delivery, tunable dissolution, and CAPRO-enhanced layers — for OTC and Rx markets simultaneously.
Our platforms

Two proprietary platforms.
One engine for every formulation challenge.

CAPRO™ handles the performance problem. MORE™ handles the delivery and experience problem. Used independently or together, they address the full formulation lifecycle.

2 Issued Patents · New excipient class
CAPRO™
Excipient Platform — Injectable · Oral · Topical · Transdermal

A patented biodegradable polymer excipient platform. Functional blocks and cleavable linkers pre-program release kinetics at the molecular level — for injectable, oral, and topical applications. Room temperature, solvent-free, no acidic byproducts. Works for small molecules AND biologics.

Solubility enhancement
Unlocks BCS II/IV molecules — higher apparent solubility without modifying API chemistry
Biologic stabilization
Preserves protein and peptide structural integrity during formulation — heat-stable to 75°C, cold chain elimination demonstrated in vivo.
Controlled release
Zero or first-order kinetics pre-programmed into the backbone — not dependent on in vivo conditions
Long-acting injectable (LAI)
SubQ, IM, intra-articular depots from days to months — 505(b)(2) pathway, GMP-compatible process in development
0
Harmful solvents
Room-temp physical mixing
Zero
Burst release
Kinetics pre-programmed by design
505(b)(2)
Regulatory path
API unchanged · Pre-IND confirmed
Explore CAPRO™
Patent pending · OTC + Rx · CAPRO-enhanced
MORE™
Oral Delivery Platform — Sublingual & buccal wafer

A patent-pending multi-layer oral wafer platform. Dissolves without water, delivers transumsocally, and can be enhanced with CAPRO™ for poorly soluble APIs. Up to 6 independently engineered layers — fast, extended, or biphasic kinetics built in before manufacture.

No water required
Dissolves sublingually — removes the #1 compliance barrier. Up to 50% of patients skip daily meds.
Tunable dissolution
Fast, extended, or biphasic profiles — engineered into the multi-layer architecture before manufacture
Transmucosal delivery
Bypasses GI degradation and first-pass metabolism — faster onset, more consistent systemic exposure
OTC + Rx dual market
Sleep, energy, oral pain (OTC) and CNS, acute pain (Rx) — same platform, two revenue timelines
6
Engineered layers
Max per wafer
OTC
Near-term revenue
No IND required
Rx
505(b)(2) path
Known API safety data
Explore MORE™
Therapeutic areas & molecule types

Two platforms. Broad application across every molecule type.

CAPRO™ and MORE™ address formulation challenges across small molecule drugs, biologics, vaccines, and drug combinations — in injectable, oral, and topical delivery formats.

Depot · IA · SubQ
Pain
LAI depot · IA joint · OTC wafer
Sublingual · IM · Monthly
CNS
Sublingual wafer · Monthly LAI
SubQ LAI · Tumor depot
Oncology
SubQ LAI · Tumor depot · Vaccine
6-month LAI · Biologic
HIV / Infectious
6-month LAI · Biologic depot
MORE™ wafer Sleep · Energy · Oral pain
Consumer Health
OTC wafer · Sleep · Energy · Pain
505(b)(2)
All Rx programs
Existing API safety data leveraged — faster, lower-cost path to NDA
Pre-IND
FDA feedback received
Regulatory path confirmed for CAPRO™ — pre-clinical manufacturing underway
OTC
No IND for MORE™
Near-term revenue path — launches faster, validates platform commercially
GMP
Manufacturing ready
Scalable processes developed and validated in-house — partner-ready today
Commercialization strategy

Near-term OTC revenue. Long-term Rx pipeline.

Trekka's dual-platform model generates revenue on two timelines simultaneously — with the OTC path funding the Rx pipeline, not competing with it.

MORE™ — Path 1: Near-term
OTC Consumer Health — Faster to market, early revenue
✓
No IND required — OTC approval path significantly reduces regulatory burden and time to revenue
✓
Proven category disruption — sleep aids, energy supplements, oral pain products all ripe for wafer format innovation
✓
Platform validation — commercial OTC success demonstrates manufacturing quality and patient acceptance to Rx partners
✓
Self-funding — OTC revenue funds CAPRO™ Rx programs without requiring additional dilutive capital raises
SleepEnergyOral painOral health
CAPRO™ + MORE™ — Path 2: Long-term
Rx Pharmaceutical — 505(b)(2), proprietary programs + licensing
✓
505(b)(2) speed advantage — known API, established safety baseline, existing clinical data leveraged for faster IND to NDA
✓
Proprietary pipeline — LAI pain depot, CNS sublingual, oncology vaccine — all designed for 505(b)(2) from day one
✓
Platform licensing — partners license CAPRO™ or MORE™ for their own APIs; Trekka earns royalties on every unit sold globally
✓
Lifecycle extension — approved drugs facing generic competition reformulated into differentiated, IP-protected delivery products
CNSPain LAIOncologyAutoimmune
Why Trekka

What no other drug delivery partner
brings to the table.

Two proprietary platforms. GMP-compatible processes. 505(b)(2) regulatory strategy from day one. And a commercial model that generates OTC revenue while the Rx pipeline advances.

Two platforms — not one
CAPRO™ handles the performance problem (solubility, stability, release, LAI). MORE™ handles the delivery problem (format, compliance, absorption). They combine. Most formulation partners have one tool.
Broader capability
GMP-ready formulation processes
CAPRO™ and MORE™ use scalable, GMP-compatible processes designed for straightforward technology transfer to a CMO partner — no proprietary equipment, no exotic conditions.
CMO transfer-ready
505(b)(2) designed in from day one
API structure unchanged — full established safety database preserved. Pre-IND FDA feedback received. Every Rx program is designed for 505(b)(2) from molecule evaluation, not retrofitted at the end of development.
Regulatory-first
Zero burst. No solvents. No acid.
PLGA releases 20–25% on day 1, generates acidic byproducts, and requires organic solvents that damage biologics. CAPRO™ eliminates all three — a cleaner safety profile that simplifies every regulatory conversation.
vs legacy PLGA
OTC + Rx on the same platform
MORE™ generates near-term OTC revenue while CAPRO™ advances Rx programs. The OTC path validates the platform commercially and funds further development — without additional dilution.
Dual revenue
Room temperature. No heat. No degradation.
Most excipient formulations require high heat — which degrades the API and creates scale-up failures as batch size increases. CAPRO™ uses physical mixing at room temperature, preserving full API structural integrity from lab scale to commercial manufacture.
Scale-up advantage
Have a molecule that needs unlocking?
Tell us what you're working on.
Trekka partners with pharma, biotech, and consumer health companies facing formulation challenges that limit what their molecules can do. All inquiries treated confidentially. Response within 48 hours.